Indirect buyers seek final nod for Jazz, Hikma settlements in Xyrem US antitrust case
MLex Summary: Indirect purchasers of Xyrem asked a US federal judge to grant final approval to their $195 million settlements with Jazz Pharmaceuticals and Hikma Pharmaceuticals to resolve an antitrust case...To view the full article, register now.
Already a subscriber? Click here to view full article